(Q33428751)

26 July 2017

A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer (English)

1 reference

26 July 2017

1 reference

Sang Hoon Ji

1

1 reference

26 July 2017

Do Hyoung Lim

2

1 reference

26 July 2017

Seong Yoon Yi

3

1 reference

26 July 2017

Hyo Song Kim

4

1 reference

26 July 2017

Hyun Jung Jun

5

1 reference

26 July 2017

Kyoung Ha Kim

6

1 reference

26 July 2017

Myung Hee Chang

7

1 reference

26 July 2017

Min Jae Park

8

1 reference

26 July 2017

Ji Eun Uhm

9

1 reference

26 July 2017

Jeeyun Lee

10

1 reference

26 July 2017

Se Hoon Park

11

1 reference

26 July 2017

Joon Oh Park

12

1 reference

26 July 2017

Young Suk Park

13

1 reference

26 July 2017

Ho Yeong Lim

14

1 reference

26 July 2017

Won Ki Kang

15

1 reference

26 July 2017

language of work or name

English

0 references

publication date

9 April 2009

1 reference

26 July 2017

1 reference

26 July 2017

9

1 reference

26 July 2017

110

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2407-9-110

26 July 2017

0 references

cites work

Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671521

HER-2/neu amplification is an independent prognostic factor in gastric cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671521

Review of second-line chemotherapy for advanced gastric adenocarcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671521

Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671521

The role of chemotherapy in the current treatment of gastric cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671521

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671521

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671521

Annual Report of the Korea Central Cancer Registry Program 2000: Based on Registered Data from 131 Hospitals

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-110

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-110

Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-110

Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-110

Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-110

Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-110

Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-110

Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19358705

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19358705

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19358705

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2407-9-110

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference